Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) Gross Margin (2016 - 2023)

Historic Gross Margin for RedHill Biopharma (RDHL) over the last 9 years, with Q2 2023 value amounting to 55.12%.

  • RedHill Biopharma's Gross Margin rose 41500.0% to 55.12% in Q2 2023 from the same period last year, while for Jun 2023 it was 42.74%, marking a year-over-year increase of 11100.0%. This contributed to the annual value of 60.31% for FY2024, which is 132800.0% up from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's Gross Margin is 55.12%, which was up 41500.0% from 55.21% recorded in Q1 2023.
  • RedHill Biopharma's Gross Margin's 5-year high stood at 75.99% during Q1 2019, with a 5-year trough of 62.41% in Q1 2020.
  • Its 5-year average for Gross Margin is 43.77%, with a median of 50.7% in 2020.
  • Its Gross Margin has fluctuated over the past 5 years, first crashed by -1384000bps in 2020, then skyrocketed by 1125700bps in 2021.
  • Over the past 5 years, RedHill Biopharma's Gross Margin (Quarter) stood at 50.44% in 2019, then fell by 0bps to 50.37% in 2020, then plummeted by -75bps to 12.4% in 2021, then soared by 165bps to 32.82% in 2022, then soared by 68bps to 55.12% in 2023.
  • Its Gross Margin was 55.12% in Q2 2023, compared to 55.21% in Q1 2023 and 32.82% in Q4 2022.